Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mefartem
- Development stage
- Phase 4
- Lead developer
- Annygod
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mefartem is a fixed-dose combination antimalarial medication containing artemether and lumefantrine. It is marketed by Annygod and manufactured by Alpa Laboratories. Mefartem is indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including in areas with reported chloroquine resistance. Artemether, an artemisinin derivative, acts rapidly to reduce parasite biomass, while lumefantrine has a longer half-life and clears any remaining parasites to prevent recrudescence.
- Brand names
- MefartemMefartem 20Mefartem20Mefartem-20Mefartem 80/480
- Other names
- artemether + lumefantrineartemether/lumefantrine
02
Targets
HemeATP2A (Sarcoplasmic reticulum Ca2+-ATPase)
Beyond the preview
Go deeper on Mefartem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mefartem.